fluorobenzenes has been researched along with Kidney Diseases in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Campese, VM | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Aukrust, P; Block, D; Gullestad, L; Kjekshus, J; McMurray, JJ; Nymo, SH; Ueland, T; Wienhues-Thelen, UH; Wikstrand, J; Zaugg, C | 1 |
| Wolfe, S | 1 |
| Kapur, NK; Musunuru, K | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Benardón, ME; Bocanegra, V; Kurbán, F; Manucha, W; Mazzei, L; Tosi, MR; Vallés, P | 1 |
| Farias, RE; Ferreira, AP; Girardi, JM; Raposo, NR | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Benardón, ME; Cuello-Carrión, FD; García, IM; Gil Lorenzo, A; Manucha, W; Mazzei, L; Oliveros, L; Vallés, PG | 1 |
| An, WS; Kim, KH; Kim, MH; Kim, SE; Lee, SJ; Lee, SM; Nam, HK; Rho, JH; Son, YK | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Grundy, SM | 1 |
| Alsheikh-Ali, AA; Ambrose, MS; Karas, RH; Kuvin, JT | 1 |
| Dedon, PC; Gilman, S; Glassock, RJ; Gogolak, V; Gordis, L; Guengerich, FP; Muñoz, A; Wasserman, SI; Witztum, JL; Wogan, GN; Zipes, DP; Zvaifler, NJ | 1 |
| Aurich-Barrera, B; Cornelius, V; Kasliwal, R; Shakir, SA; Wilton, LV | 1 |
| Guthrie, RM; Martin, DR | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| De Schepper, PJ; Mullie, A; Tjandramaga, TB; Verbeeck, R; Verberckmoes, R | 1 |
6 review(s) available for fluorobenzenes and Kidney Diseases
| Article | Year |
|---|---|
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Clinical efficacy and safety of statins in managing cardiovascular risk.
Topics: Atherosclerosis; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Rosuvastatin: an independent analysis of risks and benefits.
Topics: Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Muscular Diseases; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides | 2006 |
The safety of rosuvastatin: effects on renal and hepatic function.
Topics: Animals; Chemical and Drug Induced Liver Injury; Fluorobenzenes; Humans; Kidney; Kidney Diseases; Liver; Liver Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
3 trial(s) available for fluorobenzenes and Kidney Diseases
| Article | Year |
|---|---|
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Predictive value of endostatin in chronic heart failure patients with poor kidney function.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Endostatins; Female; Fluorobenzenes; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Kidney Diseases; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2015 |
Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Pressure; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cystatin C; Diabetic Nephropathies; Female; Fluorobenzenes; Glycemic Index; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
12 other study(ies) available for fluorobenzenes and Kidney Diseases
| Article | Year |
|---|---|
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
Topics: Advertising; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrimidines; Rhabdomyolysis; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; United States; United States Food and Drug Administration | 2015 |
eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.
Topics: Animals; Animals, Newborn; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cytoprotection; Female; Fluorobenzenes; HSP70 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Inbred WKY; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase; Ureteral Obstruction | 2011 |
Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.
Topics: Animals; Blood Pressure; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukins; Kidney Diseases; Male; Nephritis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Plethysmography; Proteinuria; Pyrimidines; Random Allocation; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy.
Topics: Animals; Animals, Newborn; Caveolin 1; Female; Fluorobenzenes; HSP70 Heat-Shock Proteins; Humans; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Protective Agents; Pyrimidines; Rats; Rats, Inbred WKY; Rosuvastatin Calcium; Sulfonamides; Ureteral Obstruction | 2012 |
Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy.
Topics: Actins; Animals; Apoptosis; Cadherins; Cyclosporine; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; JNK Mitogen-Activated Protein Kinases; Kidney; Kidney Diseases; Male; MAP Kinase Signaling System; Nitric Oxide Synthase Type II; Proteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Smad Proteins; Sulfonamides; Transforming Growth Factor beta1 | 2013 |
The issue of statin safety: where do we stand?
Topics: Chemical and Drug Induced Liver Injury; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lipoproteins, LDL; Pyridines; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
Topics: Consumer Product Safety; Drug Evaluation; Drug Prescriptions; Fluorobenzenes; Humans; Kidney Diseases; Morbidity; Product Surveillance, Postmarketing; Proteinuria; Pyridines; Pyrimidines; Renal Insufficiency; Retrospective Studies; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2005 |
Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cohort Studies; Dose-Response Relationship, Drug; Drug Prescriptions; England; Family Practice; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Liver Function Tests; Male; Middle Aged; Muscular Diseases; Product Surveillance, Postmarketing; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Time Factors | 2007 |
Rosuvastatin: renal disorders and rhabdomyolysis.
Topics: Clinical Trials as Topic; Drug Approval; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrimidines; Rhabdomyolysis; Sulfonamides | 2007 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Pharmacokinetics of diflunisal elimination in patients with renal insufficiency [proceedings].
Topics: Fluorobenzenes; Humans; Kidney Diseases; Kinetics; Salicylates | 1977 |